NeuCyte, Inc.

NeuCyte is an early-stage, preclinical biotechnology company focused on developing novel treatments for neurological disorders. The company utilizes its proprietary SynFire® technology to generate human induced pluripotent stem cell (iPSC)-derived neural cells, creating highly functional in vitro platforms for disease modeling, neurotoxicity testing, and phenotypic drug discovery. By focusing on human-specific neural phenotypes that are often not captured in traditional animal models, NeuCyte aims to improve the predictive accuracy of drug discovery for complex CNS conditions. The company is actively engaged in research and development for disorders such as epilepsy, Fragile X Syndrome, and ALS, often collaborating with academic and research institutions to advance its pipeline.